Copyright
©The Author(s) 2020.
World J Gastroenterol. Dec 21, 2020; 26(47): 7528-7537
Published online Dec 21, 2020. doi: 10.3748/wjg.v26.i47.7528
Published online Dec 21, 2020. doi: 10.3748/wjg.v26.i47.7528
Table 1 Baseline demographic and disease characteristics of inflammatory bowel disease population
| Parameter | mean ± SD or n (%) |
| Age (yr) | 46.2 ± 13.2 |
| Sex | |
| Male | 474 (58.7) |
| Female | 333 (41.3) |
| Smokers | 132 (16.4) |
| BMI (kg/m2) | 24.5 ± 5.0 |
| CD | 438 (54.2) |
| UC | 369 (45.8) |
| IBD age onset | 20.0 ± 9.4 |
| HBI | 1.3 ± 2.4 |
| CD behavior | |
| Inflammatory B1 | 237 (54.1) |
| Stricturing B2 | 128 (29.2) |
| Penetrating B3 | 60 (16.7) |
| CD extension | |
| L1 Ileal | 198 (45.2) |
| L2 colic | 44 (10.0) |
| L3 ileocolic | 164 (37.4) |
| Perianal | 3 (0.68) |
| L4 upper GI | 16 (3.6) |
| UC extension | |
| Proctitis E1 | 164 (44.4) |
| Left colitis E2 | 55 (14.9) |
| Pancolitis E3 | 123 (40.7) |
| Mayo Score | 1.7 ± 1 |
| CD previous surgery | 109 (24.9) |
| Colectomy for UC | 30 (8.1) |
| Azathioprine | 300 (37.2) |
| Systemic corticosteroids | |
| < 3 courses/yr | 471 (58.4) |
| > 3 courses/yr | 101 (12.5) |
| Topical corticosteroids | |
| In course | 94 (11.6) |
| Previously taken | 190 (23.5) |
| Infliximab | 147 (18.2) |
| Adalimumab | 131 (16.2) |
| Golimumab | 28 (3.5) |
| Vedolizumab | 35 (4.3) |
| Antibiotics | 451 (55.9) |
| Diabetes | 39 (4.8) |
| Hypertension | 79 (9.8) |
| Waist circumference (> 102 cm males, > 88 females) | 138 (17.1) |
| Liver steatosis | 232 (28.7) |
- Citation: Losurdo G, La Fortezza RF, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study. World J Gastroenterol 2020; 26(47): 7528-7537
- URL: https://www.wjgnet.com/1007-9327/full/v26/i47/7528.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i47.7528